ReviewInfection and drug resistance2019
Clinical utility of tafenoquine in the prevention of relapse of
Review in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05203744 (Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Mechanistic perspectives on antimalarial agents: from FDA-approved drugs to next-generation candidates.RSC advances · 2026Review
- Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi.Parasites & vectors · 2026Article
- Cethromycin pharmacokinetics and pharmacodynamics for single dose cure ofAntimicrobial agents and chemotherapy · 2025Article
- Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.Malaria journal · 2024Review
- Article
- Single-cell quantitative bioimaging ofmSphere · 2023Article
- Tafenoquine for the radical cureThe Indian journal of medical research · 2023Article
- Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Performance of a Commercial Multiplex Allele-Specific Polymerase Chain Reaction Kit to Genotype African-Type Glucose-6-Phosphate Dehydrogenase Deficiency.The American journal of tropical medicine and hygiene · 2023Article
- An Efficient and Sustainable Synthesis of the Antimalarial Drug Tafenoquine.ACS sustainable chemistry & engineering · 2022Article
- Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.Tropical diseases, travel medicine and vaccines · 2022Review
- Mechanisms of 8-aminoquinoline induced haemolytic toxicity in a G6PDd humanized mouse model.Journal of cellular and molecular medicine · 2022Article
- Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.Frontiers in cellular and infection microbiology · 2022Review
- Host-parasite interactions duringFrontiers in immunology · 2022Review
- Host-directed therapy, an untapped opportunity for antimalarial intervention.Cell reports. Medicine · 2021Review
- Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania.Infectious diseases of poverty · 2021Article
- Tafenoquine Is a Promising Drug Candidate for the Treatment of Babesiosis.Antimicrobial agents and chemotherapy · 2021Article
- Tafenoquine forThe Indian journal of medical research · 2021Review
- Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action.Molecules (Basel, Switzerland) · 2021Review
- Relapses ofBMJ global health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.